President and CEO
Carter Cliff joined as CEO of Tacitus Therapeutics in 2019, bringing over 15 years of experience creating and advancing innovative life science companies from inception to early clinical stage. Prior to Tacitus, he co-founded four successful biotech companies focused in the areas of regenerative medicine and precision medicine, including Opsis Therapeutics, a biotech developing photoreceptor replacement therapy for retinal diseases. Prior to Opsis, he directed the development of Cellular Dynamics International’s induced-pluripotent stem cell (iPSC) therapeutic pipeline through their listing on NASDAQ and subsequent acquisition by FUJIFILM for $307M.
Ronald Hoffman, MD
Ronald Hoffman, MD, is a scientific co-founder of Tacitus Therapeutics and the Director of Myeloproliferative Neoplasms (MPN) Research Consortium at Icahn School of Medicine at Mount Sinai, New York. Dr. Hoffman is also the Albert A. and Vera G. List Professor of Medicine at the Tisch Cancer Institute at Mount Sinai. His research and clinical work concentrate on diagnosing and treating patients with MPN and on hematopoietic stem cell biology. Dr. Hoffman has held the position of President of the American Society of Hematology and The International Society of Experimental Hematology and is the editor of the textbook Hematology Basic Principles and Practice. Dr. Hoffman held previous academic positions at Yale University, Indiana University School of Medicine, and University of Illinois College of Medicine in Chicago, and was the vice president of research at SyStemix Inc., Palo Alto, California. Dr. Hoffman earned his MD from New York University and trained at Stanford University, California; McGill University, Montreal; and Mount Sinai School of Medicine, New York.
Camelia Iancu-Rubin, PhD
Camelia Iancu-Rubin, PhD, is a scientific co-founder of Tacitus Therapeutics and the Director of Cellular Therapies Laboratory at Mount Sinai Hospital in New York. She is also an Associate Professor in the Department of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai. Her long-standing research interests are megakaryopoiesis and thrombopoiesis. She was the scientific director of the Hematological Malignancies Tissue Bank of the Tisch Cancer Institute at Mount Sinai, where she still holds an academic appointment. Dr. Iancu-Rubin earned her PhD in biological sciences from the University of Bucharest in Romania and the Graduate School of Biomedical Sciences at Mount Sinai. She was a Fulbright Scholar of the International Educational Program for the U.S. government.
Luena Papa, PhD
Luena Papa, PhD, is an Assistant Professor at the Division of Hematology/Medical Oncology at the Icahn School of Medicine at Mount Sinai in New York City. She received her PhD in Molecular and Cellular Biology from the City University of New York. Her long-standing research interest is the elucidation of mitochondrial metabolic reprogramming in normal hematopoiesis, as well as hematologic and solid malignancies. Currently, her studies focus on understanding the mechanisms underlying the ex vivo expansion of hematopoietic stem cells from CD34+ cells derived from umbilical cord blood with valproic acid treatment.
Christoph Schaniel, PhD
Christoph Schaniel, PhD, is an Assistant Professor at the Black Family Stem Cell Institute, the Mount Sinai Institute for Systems Biomedicine and the Departments of Pharmacological Sciences and Cell, Developmental and Regenerative Biology at the Icahn School of Medicine at Mount Sinai in New York. He received his PhD in Cell Biology from the University of Basel and the Basel Institute for Immunology in Switzerland and trained at Princeton University. Dr. Schaniel is an immunologist with extensive expertise in stem cell biology, including hematopoietic and pluripotent stem cells, cellular reprogramming and disease modeling.
Bartek Jablonski, MS
Bartek Jablonski is the Project Manager for the Consortium to Accelerate Therapeutic Applications of Stem Cells at Icahn School of Medicine at Mount Sinai. His role includes working with R&D scientists, GMP manufacturers, clinicians, and finance leaders/sponsors to strategize and obtain regulatory and FDA approvals for clinical trials. He received his undergraduate degree in Biology from Loyola University Chicago, and his Master’s degree in Biology from New York University.